Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
KMT2A rearranged infant acute lymphoblastic leukemia patients have a poor prognosis. Here, the authors use high throughput drug screening on primary infant specimens to identify a clinically active chemotherapy combination.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-36370-x |
| _version_ | 1827983673763299328 |
|---|---|
| author | Jennifer L. Kamens Stephanie Nance Cary Koss Beisi Xu Anitria Cotton Jeannie W. Lam Elizabeth A. R. Garfinkle Pratima Nallagatla Amelia M. R. Smith Sharnise Mitchell Jing Ma Duane Currier William C. Wright Kanisha Kavdia Vishwajeeth R. Pagala Wonil Kim LaShanale M. Wallace Ji-Hoon Cho Yiping Fan Aman Seth Nathaniel Twarog John K. Choi Esther A. Obeng Mark E. Hatley Monika L. Metzger Hiroto Inaba Sima Jeha Jeffrey E. Rubnitz Junmin Peng Taosheng Chen Anang A. Shelat R. Kiplin Guy Tanja A. Gruber |
| author_facet | Jennifer L. Kamens Stephanie Nance Cary Koss Beisi Xu Anitria Cotton Jeannie W. Lam Elizabeth A. R. Garfinkle Pratima Nallagatla Amelia M. R. Smith Sharnise Mitchell Jing Ma Duane Currier William C. Wright Kanisha Kavdia Vishwajeeth R. Pagala Wonil Kim LaShanale M. Wallace Ji-Hoon Cho Yiping Fan Aman Seth Nathaniel Twarog John K. Choi Esther A. Obeng Mark E. Hatley Monika L. Metzger Hiroto Inaba Sima Jeha Jeffrey E. Rubnitz Junmin Peng Taosheng Chen Anang A. Shelat R. Kiplin Guy Tanja A. Gruber |
| author_sort | Jennifer L. Kamens |
| collection | DOAJ |
| description | KMT2A rearranged infant acute lymphoblastic leukemia patients have a poor prognosis. Here, the authors use high throughput drug screening on primary infant specimens to identify a clinically active chemotherapy combination. |
| first_indexed | 2024-04-09T22:49:06Z |
| format | Article |
| id | doaj.art-2cd886b587c94bdaa2bd04fdff849913 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-09T22:49:06Z |
| publishDate | 2023-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-2cd886b587c94bdaa2bd04fdff8499132023-03-22T11:41:05ZengNature PortfolioNature Communications2041-17232023-02-0114111310.1038/s41467-023-36370-xProteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemiaJennifer L. Kamens0Stephanie Nance1Cary Koss2Beisi Xu3Anitria Cotton4Jeannie W. Lam5Elizabeth A. R. Garfinkle6Pratima Nallagatla7Amelia M. R. Smith8Sharnise Mitchell9Jing Ma10Duane Currier11William C. Wright12Kanisha Kavdia13Vishwajeeth R. Pagala14Wonil Kim15LaShanale M. Wallace16Ji-Hoon Cho17Yiping Fan18Aman Seth19Nathaniel Twarog20John K. Choi21Esther A. Obeng22Mark E. Hatley23Monika L. Metzger24Hiroto Inaba25Sima Jeha26Jeffrey E. Rubnitz27Junmin Peng28Taosheng Chen29Anang A. Shelat30R. Kiplin Guy31Tanja A. Gruber32Department of Pediatrics, Stanford University School of MedicineDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Computational Biology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Pediatrics, Stanford University School of MedicineThe University of Tennessee Health Science CenterDepartment of Pediatrics, Stanford University School of MedicineDepartment of Pediatrics, Stanford University School of MedicineDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Pathology, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalCenter for Proteomics and Metabolomics, St. Jude Children’s Research HospitalCenter for Proteomics and Metabolomics, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalCenter for Proteomics and Metabolomics, St. Jude Children’s Research HospitalDepartment of Computational Biology, St. Jude Children’s Research HospitalDepartment of Pathology, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Pathology, University of Alabama School of MedicineDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalDepartment of Oncology, St. Jude Children’s Research HospitalCenter for Proteomics and Metabolomics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Chemical Biology and Therapeutics, St. Jude Children’s Research HospitalDepartment of Pharmaceutical Sciences, University of KentuckyDepartment of Pediatrics, Stanford University School of MedicineKMT2A rearranged infant acute lymphoblastic leukemia patients have a poor prognosis. Here, the authors use high throughput drug screening on primary infant specimens to identify a clinically active chemotherapy combination.https://doi.org/10.1038/s41467-023-36370-x |
| spellingShingle | Jennifer L. Kamens Stephanie Nance Cary Koss Beisi Xu Anitria Cotton Jeannie W. Lam Elizabeth A. R. Garfinkle Pratima Nallagatla Amelia M. R. Smith Sharnise Mitchell Jing Ma Duane Currier William C. Wright Kanisha Kavdia Vishwajeeth R. Pagala Wonil Kim LaShanale M. Wallace Ji-Hoon Cho Yiping Fan Aman Seth Nathaniel Twarog John K. Choi Esther A. Obeng Mark E. Hatley Monika L. Metzger Hiroto Inaba Sima Jeha Jeffrey E. Rubnitz Junmin Peng Taosheng Chen Anang A. Shelat R. Kiplin Guy Tanja A. Gruber Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia Nature Communications |
| title | Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia |
| title_full | Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia |
| title_fullStr | Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia |
| title_full_unstemmed | Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia |
| title_short | Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia |
| title_sort | proteasome inhibition targets the kmt2a transcriptional complex in acute lymphoblastic leukemia |
| url | https://doi.org/10.1038/s41467-023-36370-x |
| work_keys_str_mv | AT jenniferlkamens proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT stephanienance proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT carykoss proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT beisixu proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT anitriacotton proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT jeanniewlam proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT elizabethargarfinkle proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT pratimanallagatla proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT ameliamrsmith proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT sharnisemitchell proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT jingma proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT duanecurrier proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT williamcwright proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT kanishakavdia proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT vishwajeethrpagala proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT wonilkim proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT lashanalemwallace proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT jihooncho proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT yipingfan proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT amanseth proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT nathanieltwarog proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT johnkchoi proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT estheraobeng proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT markehatley proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT monikalmetzger proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT hirotoinaba proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT simajeha proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT jeffreyerubnitz proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT junminpeng proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT taoshengchen proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT anangashelat proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT rkiplinguy proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia AT tanjaagruber proteasomeinhibitiontargetsthekmt2atranscriptionalcomplexinacutelymphoblasticleukemia |